Finally, to examine if MX69 could further exert anti-myeloma effects with BTZ, we treated xenograft mice through intraperitoneal injection twice a week with 0.5 mg/kg BTZ alone, three times a week with 50 mg/kg MX69 alone or combined with 0.5 mg/kg BTZ, or an equal volume of vehicle for 21 days. This evidence concerns the gene CASC3 and plasma cell myeloma.